DGAT2 Antisense Compounds for Triglyceride Synthesis Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver diseases (NAFLD) such as nonalcoholic steatohepatitis (NASH) and lipodystrophy syndromes, including partial lipodystrophy, are inadequate, as patients often fail to maintain lifestyle modifications, and conventional therapies are not efficacious in reducing triglycerides and improving insulin sensitivity.
Innovation Solution
Administration of DGAT2-specific inhibitors, particularly antisense compounds targeting DGAT2 nucleic acids, to inhibit DGAT2 expression and activity, thereby reducing triglyceride synthesis and improving hepatic steatosis and insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifestyle modification (diet and exercise) is implemented, then triglyceride levels and insulin sensitivity may improve, but patient adherence is poor and treatment effectiveness is insufficient
Solution Approach 1:
The patent replaces the mechanical/lifestyle-based treatment approach (diet and exercise) with a pharmacological system (DGAT2 inhibitors) that directly targets the biochemical pathway of triglyceride synthesis. This substitution enables more reliable and consistent treatment effectiveness without relying on patient behavior modification.
Solution Approach 2:
The patent changes the fundamental parameter of treatment mechanism from lifestyle modification to direct pharmacological inhibition of DGAT2 enzyme activity. This parameter change results in more predictable and reliable treatment outcomes, as the drug directly affects the biochemical process rather than relying on indirect lifestyle changes.
2Reliability
If conventional therapies (metformin, thiazolidinediones, fibrates) are used, then diabetes and elevated TG levels are treated, but efficacy in reducing triglycerides and improving insulin sensitivity is insufficient
Solution Approach 1:
The patent extracts and specifically targets the DGAT2 enzyme, which is responsible for the final step in triglyceride synthesis. By isolating and inhibiting this specific enzyme rather than using broad-spectrum conventional therapies, the patent achieves superior triglyceride reduction and insulin sensitivity improvement.
Solution Approach 2:
The patent changes the therapeutic parameter from conventional diabetes medications (metformin, thiazolidinediones, fibrates) to DGAT2-specific inhibitors. This parameter change enables direct inhibition of triglyceride synthesis, resulting in more effective reduction of triglycerides and improvement of insulin sensitivity compared to conventional therapies.
3Reliability
If DGAT2 inhibition is achieved through antisense compounds, then triglyceride synthesis is reduced and hepatic steatosis improves, but compound complexity and administration requirements increase
Solution Approach 1:
The patent uses antisense compounds as intermediaries that bind to DGAT2 mRNA and prevent translation into functional enzyme. This intermediary mechanism allows for specific and reliable inhibition of DGAT2 activity, leading to improved hepatic steatosis treatment outcomes.
Solution Approach 2:
The patent changes the approach from direct enzyme inhibition to mRNA-level intervention using antisense compounds. This parameter change enables more specific and reliable targeting of DGAT2, resulting in improved hepatic steatosis reduction while managing the complexity through established molecular biology techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DGAT2 inhibitors effectively reduce triglycerides, improve insulin sensitivity, and slow the progression of NAFLD and lipodystrophy syndromes, providing a more potent and tolerable treatment option than existing therapies.
Implementation Method 1
antisense compounds targeting DGAT2 nucleic acids
Implementation Method 2
inhibit DGAT2 expression and activity, thereby reducing triglyceride synthesis
Data Source
AI summary
The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.